Literature DB >> 6981161

Long-term antimicrobial prophylaxis for recurrent urinary tract infection in women.

G K Harding, A R Ronald, L E Nicolle, M J Thomson, G J Gray.   

Abstract

Thirteen women and two preadolescent girls who suffered recurrences after six months of prophylaxis with trimethoprim (TMP; 40 mg) and sulfamethoxazole (SMZ; 200 mg) taken thrice weekly at bedtime were enrolled in a 24-month study of prophylaxis with the same region. During 29.1 cumulative patient-years of prophylaxis, two infections due to Escherichia coli and one each due to Staphylococcus epidermidis and Streptococcus faecalis occurred (0.14 infection/patient-year). MICs for these isolates were less than or equal to 2 micrograms of TMP/ml and greater than 512 micrograms of SMZ/ml. During prophylaxis, 106 of 116 cultures from the periurethral area and 66 of 97 cultures from the anal and canal yielded no aerobic gram-negative bacilli. In three patients, the periurethral area was colonized with aerobic gram-negative bacilli with MICs of greater than or equal to 2 micrograms of TMP/ml. Thirteen patients were followed after the discontinuation of prophylaxis. Eight suffered recurrences, seven with organisms susceptible to TMP. After one year the remaining five had experienced no recurrences. It is concluded that long-term prophylaxis with 40 mg of TMP and 200 mg of SMZ thrice weekly is an effective, well-tolerated regimen that can maintain an infection-free state in women with histories of frequent urinary reinfections.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981161     DOI: 10.1093/clinids/4.2.438

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  9 in total

1.  Trimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions.

Authors:  M A Kielhofner
Journal:  Tex Heart Inst J       Date:  1990

2.  Prophylaxis: recurrent urinary tract infection in women.

Authors:  L E Nicolle
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 3.  Chinese herbal medicine for treating recurrent urinary tract infections in women.

Authors:  Andrew Flower; Li-Qiong Wang; George Lewith; Jian Ping Liu; Qing Li
Journal:  Cochrane Database Syst Rev       Date:  2015-06-04

4.  How women manage recurrent urinary tract infections: an analysis of postings on a popular web forum.

Authors:  Andrew Flower; Felicity L Bishop; George Lewith
Journal:  BMC Fam Pract       Date:  2014-09-26       Impact factor: 2.497

Review 5.  The optimal management of lower urinary tract infections.

Authors:  L E Nicolle
Journal:  Infection       Date:  1990       Impact factor: 3.553

6.  Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora.

Authors:  D A Haase; G K Harding; M J Thomson; J K Kennedy; B A Urias; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

7.  Comparative in vitro activity of norfloxacin against urinary tract pathogens.

Authors:  D Haase; B Urias; G Harding; A Ronald
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

8.  D-MannosE to prevent Recurrent urinary tract InfecTions (MERIT): protocol for a randomised controlled trial.

Authors:  Marloes Franssen; Johanna Cook; Jared Robinson; Nicola Williams; Margaret Glogowska; Yaling Yang; Julie Allen; Christopher C Butler; Nick Thomas; Alastair Hay; Michael Moore; Gail Hayward
Journal:  BMJ Open       Date:  2021-01-13       Impact factor: 2.692

9.  Standardised Chinese herbal treatment delivered by GPs compared with individualised treatment administered by practitioners of Chinese herbal medicine for women with recurrent urinary tract infections (RUTI): study protocol for a randomised controlled trial.

Authors:  Andrew Flower; Kim Harman; George Lewith; Michael Moore; Felicity L Bishop; Beth Stuart; Nicholas Lampert
Journal:  Trials       Date:  2016-07-27       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.